Yongzhao Shao
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Year:
2026
Year:
2026
Purpose: Patients with stage II and resected stage III melanomas have variable clinical outcomes, providing evidence of underlying biological differences in tumors and/or the patients themselves, beyond stage. The approval of adjuvant immunotherapy for stage IIB/C and resected stage III/IV disease (and adjuvant targeted therapy for resected stage III disease) has created a pressing need to develop biomarkers to accurately distinguish patients at low risk versus high risk for recurrence and death from melanoma. miRNAs are promising biomarkers because of their stability in tissues and fluids and their demonstrated functional and prognostic roles in melanoma. We hypothesized that miRNA expression could be integrated into prognostic models that would classify 5-year survival outcomes more accurately than clinical factors alone. Experimental Design: Using a NanoString miRNA Expression Assay, we analyzed 715 primary melanomas from patients with stage II or stage III disease within the InterMEL consortium and examined associations between miRNA expression and melanoma-specific death. Results: When integrated into clinical prognostic models for 5-year melanoma-specific survival, miRNA signatures improved the area under the receiver operating characteristic curve for patients in stage II from 0.71 for a “clinical factors–only” model to 0.81 for a “clinical plus miRNA” model in an independent test set, an improvement of 0.10 with a 95% confidence interval (0.03–0.19). The improvement was more modest for patients in stage III who were included in the analysis. Conclusions: Incorporating miRNA expression in primary melanomas may enhance the accuracy of clinical prognostic models and potentially aid in the selection of patients with melanoma for adjuvant treatment and clinical trials.
Year:
2025
Recent mechanistic studies have indicated that combinations of radiotherapy (RT) plus immunotherapy (via CSF-1R inhibition) can serve as a strategy to overcome RT resistance and improve the survival of glioma mice. Given the high mortality rate for glioma, including low-grade glioma (LGG) patients, it is of critical importance to investigate the mechanism of the combination of RT and immunotherapy and further translate the mechanism from mouse studies to improve survival of RT-treated human glioma patients. Using the RNA-seq data from a glioma mouse study, 874 differentially expressed genes (DEGs) between the group of RT-treated mice at glioma recurrence and the group of mice with combination treatment (RT plus CSF-1R inhibition) were translated to the human genome to identify significant molecular pathways using the KEGG enrichment analysis. The enrichment analysis yields statistically significant signaling pathways, including the phosphoinositide 3-kinase (PI3K)/AKT pathway, Hippo pathway, and Notch pathway. Within each pathway, a candidate gene set was selected by Cox regression models as genetic biomarkers for resistance to RT and response to the combination of RT plus immunotherapies. Each Cox model is trained using a cohort of 295 RT-treated LGG patients from The Cancer Genome Atlas (TCGA) database and validated using a cohort of 127 RT-treated LGG patients from the Chinese Glioma Genome Atlas (CGGA) database. A four-DEG signature (ITGB8, COL9A3, TGFB2, JAG1) was identified from the significant genes within the three pathways and yielded the area under time-dependent ROC curve AUC = 0.86 for 5-year survival in the validation set, which indicates that the selected DEGs have strong prognostic value and are potential intervention targets for combination therapies. These findings may facilitate future trial designs for developing combination therapies for glioma patients.
Year:
2024
Supplementary Table S8. Confusion matrix for top LASSO-regularized and cross-validated logistic regression model predicting severe (grade 3-4) irAEs (age, stage, and CD22, PAG1, CD33, HNRNPU, and FCGR2C gene expression) in COMBO-treated patients.
Year:
2024
Supplementary Figure S5. Detailed annotation for semi-supervised hierarchical clustering of the genes associated with SYK in protein-protein interaction (PPI) analysis comparing TOXlowvs TOXhighin CD4+cells from COMBO-treated patients ( n = 78).
Year:
2024
Purpose: Immune checkpoint inhibition (ICI) shows benefits in adjuvant (AT) and neoadjuvant melanoma treatments. However, ICI frequently induces severe immune-related adverse events (irAE). Unlike metastatic disease, in which irAEs are a clinical trade-off for treatment that improves survival, the toxicity burden from ICI in the AT setting is a substantial clinical problem urging for irAE-predictive biomarkers. Experimental Design: We assessed postsurgical, pre–ICI treatment peripheral CD4 + and CD8 + T cells from clinical trial patients (CheckMate 915) treated with AT nivolumab ( n = 130) or ipilimumab/nivolumab (COMBO, n = 82). Performing RNA sequencing differential gene expression analysis, we tested baseline differences associated with severe (grades 3–5) irAEs and constructed an irAE-predictive model using least absolute shrinkage and selection operator–regularized logistic regression. Results: The analysis of predicted protein–protein interactions among differentially expressed genes in peripheral CD4 + cells revealed significant enrichment of the spleen tyrosine kinase (SYK) pathway, associated with severe irAEs in COMBO-treated patients. This gene expression signature predicted severe-irAE COMBO patients (χ 2 P value = 0.001) with 73% accuracy and was independent of disease recurrence ( P = 0.79). The irAE-predictive model incorporating this gene expression signature demonstrated 82% accuracy ( χ 2 P value = 8.91E−06). Conclusions: We identified baseline gene expression differences in key immune pathways of peripheral blood T cells from COMBO-treated patients with grades 3 to 5 irAEs and defined a SYK-related gene signature correctly identifying ∼60% of COMBO-treated patients with grades 3 to 5 irAEs. This finding aligns with our previous work linking anti-CTLA4 irAEs with a germline variant associated with high SYK expression. This gene signature may serve as a baseline biomarker of severe grade 3 to 5 irAE risk, which is especially important in AT treatment.
Year:
2024
Collaborators (27)
Leah Morales
NYU Langone Medical Center
Yuting Lu
New York University
Yidan Shi
Assistant Professor
New York University Grossman School of Medicine
Graham Mann
Professor
University of Sydney
Adam Reynolds
Research Assistant Professor
University of New Mexico
Shaofeng Yan
-
Cheryl Thompson
Professor and Associate Director for Population Sciences, Penn State Cancer Institute
Pennsylvania State University
Christopher I. Amos
Associate Director for Population and Data Science
Baylor College of Medicine
Pauline Funchain
Stanford University
Marcus Bosenberg
Professor
Yale University
Marianne Berwick
Professor
University of New Mexico
David Ollila
Professor of Surgery
University of North Carolina at Chapel Hill
Marc Ernstoff
Chief
National Institutes of Health
Anne E Cust
Deputy Director, The Daffodil Centre
University of Sydney
David Polsky
Alfred W. Kopf, M.D. Professor of Dermatologic Oncology and Professor (Clinical) of Pathology (Academic)
NYU School of Medicine
Tim Lee
The University of British Columbia
Pei-Fen Kuan
Professor
Stony Brook University
Paul Googe
Professor and Laboratory Director
University of North Carolina at Chapel Hill
James Wilmott
Associate Professor
The University of Sydney Library
Iman Osman
NYU Langone Health
Eva Hernando
Professor
NYU Langone Medical Center
Jiahan xiong
NYU Langone Health
Alan Arslan
Associate Professor
NYU Langone Medical Center
Sheri L. Holmen
Professor
University of Utah Health Sciences Center
Tomas Kirchhoff
Assistant Professor of Population Health and Environmental Medicine
NYU School of Medicine
Richard A. Scolyer
Faculty Member
University of Sydney
E. Nagore
Profesor Asociado
Universidad Católica de Valencia San Vicente Mártir Facultad de Medicina Facultad de Medicina y Odontología
Make your next move.
Prepare your application
Review drafts before you send them.